Literature DB >> 5553689

The relation of thymidine labeling index in human tumors in vitro to the effectiveness of 5-fluorouracil chemotherapy.

W H Wolberg, F J Ansfield.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5553689

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  7 in total

1.  Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications.

Authors:  H M Kantarjian; B Barlogie; M J Keating; R R Hall; T L Smith; K B McCredie; E J Freireich
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

2.  [Autoradiographic investigations of thymidine incorporation after long-time incubation of rat liver].

Authors:  B Helpap; R Stiens; V Grouls
Journal:  Histochemie       Date:  1973-03-26

Review 3.  Immunology of bronchial carcinoma.

Authors:  D A Evans
Journal:  Thorax       Date:  1976-10       Impact factor: 9.139

4.  Determination of proliferative compartments in human tumors.

Authors:  H M Rabes; P Carl; U Rattenhuber
Journal:  Experientia       Date:  1978-11-15

5.  Pharmacokinetics of 5-fluorouracil: inter-relationship with biochemical kinetics in monitoring therapy.

Authors:  W Sadee; C G Wong
Journal:  Clin Pharmacokinet       Date:  1977 Nov-Dec       Impact factor: 6.447

6.  Solid tumour models for the assessment of different treatment modalities: VII: single vs fractionated doses of 5-fluorouracil on two solid tumours and their hosts.

Authors:  W B Looney; M S Macleod; H A Hopkins
Journal:  Br J Cancer       Date:  1978-05       Impact factor: 7.640

7.  Two-Step Delivery: Exploiting the Partition Coefficient Concept to Increase Intratumoral Paclitaxel Concentrations In vivo Using Responsive Nanoparticles.

Authors:  Aaron H Colby; Rong Liu; Morgan D Schulz; Robert F Padera; Yolonda L Colson; Mark W Grinstaff
Journal:  Sci Rep       Date:  2016-01-07       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.